The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM
The glucagon-like peptide-1 (GLP-1) is a peptide with incretin activity and plays an important role in glycemic control as well as the improvement of insulin resistance in type 2 diabetes mellitus (T2DM). However, the short half-life of the native GLP-1 in circulation poses difficulties for clinical...
Main Authors: | Qing Wang, Haixin Guo, Wenwei Mao, Xiuping Qian, Yangang Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/4/1202 |
Similar Items
-
GLP-1 based therapeutics: Simultaneously combating T2DM and obesity
by: Kristy M Heppner, et al.
Published: (2015-03-01) -
Technological and Functional Assessment of Riboflavin Enriched Probiotic SoyCurd
by: Kapil Singh Narayan, et al.
Published: (2021-03-01) -
The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
by: Ioanna Daniilopoulou, et al.
Published: (2022-02-01) -
First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01) -
Effect of Fermented Soymilk-Honey from Different Probiotics on Osteocalcin Level in Menopausal Women
by: Sri Desfita, et al.
Published: (2021-10-01)